Pulmonx (LUNG) EBITDA (2019 - 2025)

Pulmonx (LUNG) has 7 years of EBITDA data on file, last reported at -$14.4 million in Q3 2025.

• On a quarterly basis, EBITDA fell 1.87% year-over-year to -$14.4 million in Q3 2025; TTM through Sep 2025 was -$57.2 million, a 1.77% increase from a year earlier, with the FY2024 full-year figure at -$57.7 million, up 6.83% from the prior year.
• EBITDA for Q3 2025 stood at -$14.4 million, up from -$14.8 million in the prior quarter.
• Over the last five years, EBITDA for LUNG reached as high as -$9.8 million in Q3 2021 and fell as low as -$16.4 million in Q2 2023.
• Historically, EBITDA has averaged -$14.2 million across 5 years, with a median of -$14.4 million in 2022.
• Across the five-year window, EBITDA slumped 104.69% in 2021 and rose 11.37% in 2024, its largest moves.
• Year by year, EBITDA stood at -$12.4 million in 2021, then retreated by 18.28% to -$14.6 million in 2022, then grew by 4.84% to -$13.9 million in 2023, then climbed by 3.61% to -$13.4 million in 2024, then slipped by 7.27% to -$14.4 million in 2025.
• Per Business Quant data, the three most recent EBITDA figures were -$14.4 million in Q3 2025, -$14.8 million in Q2 2025, and -$14.6 million in Q1 2025.